Growth Hormone Axis
CJC-1295 + Ipamorelin + Tesamorelin Growth Hormone Stack
Synergistic GHRH + GHRP + GHRH-analog research stack for the somatotropic axis. Mechanism, dosing, timing and UK regulatory notes.
3 peptides 12-week cycle intermediateUpdated 2026-05-16
GH pulse amplificationIGF-1 elevation researchLean tissue research
Mechanism — three-axis somatotropic research
CJC-1295 (no DAC) — mechanism of action
A modified GHRH(1–29) analogue without the DAC (Drug Affinity Complex) modification. In published research:
- Half-life ~30 min — produces a discrete GH pulse on administration.
- Binds GHRH receptor on pituitary somatotropes, increasing pulse amplitude.
- The "no DAC" variant is preferred for pulsatile research dosing; CJC-1295 with DAC has a multi-day half-life and disrupts natural GH pulsatility.
Ipamorelin — mechanism of action
A selective GHRP / ghrelin-receptor agonist. In animal-model and Phase I human research:
- Triggers GH release without significant effect on cortisol, ACTH or prolactin (selectivity advantage over earlier GHRPs).
- Synergistic with GHRH co-administration — combined pulse magnitude greater than the sum of either alone.
- Short half-life (~2 hours) supports thrice-daily research dosing.
Tesamorelin — mechanism of action
A stabilised GHRH(1–44) analogue, FDA-approved for HIV-associated lipodystrophy. In research:
- Sustained GHRH-receptor activation — increases endogenous GH and IGF-1.
- Documented reduction in visceral adipose tissue (VAT) in published Phase III trials.
- Approved for medicinal use in HIV-lipodystrophy populations only; off-label and research uses involve unapproved indications.
Full research protocol — dosing table
| Peptide | Dose | Frequency | Timing | Cycle length |
|---|---|---|---|---|
| CJC-1295 (no DAC) | 100 µg | 3x daily SC | Pre-fasted, pre-bed, post-workout | 8–12 weeks |
| Ipamorelin | 200–300 µg | 3x daily SC | Co-administered with CJC-1295 | 8–12 weeks |
| Tesamorelin | 1–2 mg | Daily SC | Evening pre-bed | 12 weeks |
Weekly research timeline
| Peptide | Wk 1 | Wk 2 | Wk 3 | Wk 4 | Wk 5 | Wk 6 | Wk 7 | Wk 8 | Wk 9 | Wk 10 | Wk 11 | Wk 12 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CJC-1295 (no DAC) | 100 µg 3x | 100 µg 3x | 100 µg 3x | 100 µg 3x | 100 µg 3x | 100 µg 3x | 100 µg 3x | 100 µg 3x | — | — | — | — |
| Ipamorelin | 300 µg 3x | 300 µg 3x | 300 µg 3x | 300 µg 3x | 300 µg 3x | 300 µg 3x | 300 µg 3x | 300 µg 3x | — | — | — | — |
| Tesamorelin | 1 mg | 1 mg | 2 mg | 2 mg | 2 mg | 2 mg | 2 mg | 2 mg | — | — | — | — |
Routes: SC = subcutaneous · IM = intramuscular · IN = intranasal · Oral · Topical.
Safety profile & regulatory note
Where to source these research peptides
Each peptide in this stack has a dedicated research monograph on PeptideAuthority.co.uk and a research-grade SKU at PeptideBarn.co.uk. All compounds are sold strictly for in vitro research.
- CJC-1295 (no DAC)Read full research Source research-grade CJC-1295 (no DAC)
- IpamorelinRead full research Source research-grade Ipamorelin
- TesamorelinRead full research Source research-grade Tesamorelin
Frequently asked research questions
GHRH (CJC-1295) increases the *amplitude* of pituitary GH pulses; GHRP (Ipamorelin) triggers the pulse itself. Together they produce a synergistic — not additive — GH release in published animal and human research.